Recursion Pharmaceuticals (RXRX) Capital Expenditures (2020 - 2025)

Recursion Pharmaceuticals has reported Capital Expenditures for 6 years, with the latest figure at $6.4 million in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures rose 396.15% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (down 34.99% YoY), and the FY2025 full-year result was $6.5 million, down 52.76% from the prior year.
• Capital Expenditures for Q4 2025 stood at $6.4 million, up from -$234000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $34.6 million in Q3 2021, with the low at -$18.7 million in Q2 2021.
• Historically, Capital Expenditures has averaged $5.0 million across 5 years, with a median of $2.8 million in 2022.
• The largest YoY upside for Capital Expenditures was 2738.6% in 2021 against a maximum downside of 2671.62% in 2021.
• Recursion Pharmaceuticals' Capital Expenditures stood at $4.5 million in 2021, then jumped by 660.89% to $34.0 million in 2022, then plunged by 121.93% to -$7.4 million in 2023, then soared by 117.43% to $1.3 million in 2024, then soared by 396.15% to $6.4 million in 2025.
• The last three Capital Expenditures figures came in at $6.4 million (Q4 2025), -$234000.0 (Q3 2025), and -$883000.0 (Q2 2025), per Business Quant data.